Highest-materiality recent filing
Diversified Healthcare Trust annual meeting elects all 7 trustees; Portnoy gets 22% withhold
All seven trustee nominees elected, including Adam Portnoy with 144.5M for and 41.2M withhold (22% against).
DHC posts investor presentation on website; no material updates disclosed
Filed under Item 7.01; presentation attached as Exhibit 99.1.
Diversified Healthcare Trust posts investor presentation; full content not provided in filing
Investor presentation posted to website on May 5, 2026, per Item 7.01 disclosure.
DHC reports Q1 2026 results but filing lacks financial details
Announced Q1 2026 results; specific financial figures not included in filing.
DHC posts investor presentation on company website
Investor presentation posted to company website on February 24, 2026.
DHC announces Q4 2025 results and 2026 guidance; no specific figures in filing
Press release and earnings presentation furnished but contain no financial figures in extracted text.
DHC discloses $17.9M incentive fee for 2025, receives $27.2M dividend from AlerisLife wind-down
Incentive management fee of $17.9M incurred for 2025, payable in cash by Jan 30, 2026.
DHC terminates management agreements with AlerisLife for 116 senior living communities
116 senior living communities transitioned from AlerisLife to seven third-party managers effective December 31, 2025.
Filed investor presentation dated December 8, 2025 as Exhibit 99.1.
DHC reports Q3 2025 results; specific figures not available in filing
Press release and earnings presentation issued on November 3, 2025 for quarter ended September 30, 2025.
DHC posts investor presentation; no specific updates available from filing text
Filed an investor presentation dated October 8, 2025, as Exhibit 99.1 under Item 7.01.
DHC issues $375M 7.25% senior secured notes due 2030; partially redeems 2026 notes
Completed private offering of $375M aggregate principal amount of 7.250% senior secured notes due 2030.
AlerisLife selling all assets, winding down by H1 2026; DHC expects net proceeds of $25-40M for its 34% stake.
DHC announces Q2 2025 results; details in earnings presentation not fully provided
Diversified Healthcare Trust issued summary press release and earnings presentation for Q2 2025.
DHC shareholders approve equity plan increase of 3.5M shares, extend term to 2035
Equity compensation plan approved with 164.8M for, 6.2M against; shares increased by 3.5M.
DHC posts investor presentation on website; no material updates disclosed
Investor presentation dated June 2, 2025, posted on company website.
Diversified Healthcare Trust posts investor presentation on website; no material new info disclosed
Filed an investor presentation dated May 22, 2025, under Item 7.01 Regulation FD.
DHC reports Q1 2025 earnings; details available on company website
Press release and earnings presentation furnished as exhibits; no specific financial figures included in the filing excerpt.
Diversified Healthcare Trust elects Alan L. Felder as Independent Trustee
Elected March 20, 2025, term expires at 2025 annual meeting.
DHC furnishes investor presentation; no material new information found
Filed an investor presentation on corporate website dated February 26, 2025.
DHC announces Q4 2024 results; detailed figures not extractable from text
Earnings release and supplemental presentation issued Feb 25, 2025 for quarter ended Dec 31, 2024.
Diversified Healthcare Trust sells three life science properties in San Diego for $159M
Net sales price of $159.0M for three life science properties (MUSE) with 186k rentable sq ft in San Diego.
DHC posts investor presentation; no material new information disclosed
Diversified Healthcare Trust posted an investor presentation to its website on November 18, 2024.
DHC announces Q3 2024 financial results; detailed figures not included in filing text
Press release directs to website for results and conference call details.
DHC reports Q2 2024 results; details not provided in filing text
Press release directs to DHC website for full results; no specific financial figures included.
Diversified Healthcare Trust amends bylaws and reports annual meeting results
Board adopted Fourth Amended and Restated Bylaws eliminating mandatory arbitration provisions for shareholder disputes.
Diversified Healthcare Trust closes $120M mortgage loan, corrects prior guidance error
Closed a $120 million mortgage loan on May 30, 2024.
Diversified Healthcare Trust posts investor presentation; no material updates disclosed
Investor presentation posted to company website on May 21, 2024, covering Five Star Senior Living.
DHC files Q1 2024 results; detailed financials not included in provided exhibit text
Summary press release and earnings presentation furnished for quarter ended March 31, 2024.
Press release directs to DHC website for full financial results; no EPS, revenue, or segment data provided.
Issued $940.5M senior secured notes due 2026; net proceeds ~$732M; accrues 11.25% semiannually, no cash interest unless extension.
Jennifer F. Francis resigns as President and CEO effective Dec 31, 2023; she is retiring from RMR on June 30, 2024.
DHC reports Q3 2023 earnings; no financial figures in furnished exhibits
Press release and earnings presentation furnished, but actual financial data not extractable from provided text.
DHC CFO replacement and board changes: LePage & Pierce resign, Hollis elected, Brown named CFO
Trustees Daniel F. LePage and David A. Pierce resigned effective Sept 25, 2023, with no disagreements.
DHC and OPI mutually terminate merger agreement; no termination fee
Mutual termination effective September 1, 2023; no termination fee payable by either party.
DHC and OPI adjourn merger shareholder meetings to September 6
DHC and OPI adjourned their special meetings on August 30, 2023, to continue merger discussions.
DHC announces Q2 2023 results but financial details not in filing exhibits
Diversified Healthcare Trust issued press release and earnings presentation for Q2 2023 on August 1, 2023.
DHC collateral appraised value falls below credit facility threshold, triggering event of default
Appraised value of 61 medical office and life science properties declined 22% to $1.05B from $1.34B, below $1.09B threshold.
DHC: May SHOP NOI $5.8M, down 36% from Apr; debt covenant compliance unlikely before mid-2024
May 2023 SHOP occupancy 78.1%, NOI $5.8M ($11.1M below May 2019), NOI margin 6.3%.
DHC annual meeting elects trustees, passes say-on-pay, amends bylaws for universal proxy
All seven trustees elected; Adam Portnoy received 93.99M for, 67.89M withhold (highest opposition).
DHC SHOP occupancy 78% in Apr, still 860 bps below 2019; CEO cites $700M debt maturity
April SHOP occupancy 78.0%, 860 bps below April 2019, 40 bps above March 2023.
Diversified Healthcare Trust announces Q1 2023 results; details on website
Financial results for quarter ended March 31, 2023 released.
DHC to merge with OPI; DHC shareholders receive 0.147 OPI shares each, OPI renamed
Merger: DHC merges into OPI; DHC shareholders get 0.147 OPI shares per DHC share; OPI renamed Diversified Properties Trust.
Diversified Healthcare Trust to Merge with Office Properties Income Trust in All-Share Transaction
DHC shareholders will receive 0.147 OPI shares per DHC share, a 20% premium to DHC's 30-trading day average closing price.
DHC regains Nasdaq minimum bid price compliance, matter closed
On Jan 19, 2023, DHC was notified common shares closed below $1.00 for 30 consecutive business days.
Investor presentation posted; no specific details available in filing excerpt
Filing states an investor presentation was attached as Exhibit 99.1 but the full content is not included in the provided text.
DHC Q4 2022: net loss $0.27/sh, normalized FFO $0.03/sh, SHOP occupancy up 380bps
Net loss attributable to common shareholders of $65.3M ($0.27 per share); Normalized FFO of $0.03 per share.
Facility commitments reduced from $586.4M to $450M; no further reborrowing allowed.
DHC consents to AlerisLife acquisition by ABP, agrees to tender 31.9% stake at $1.31/share
DHC owns 10,691,658 AlerisLife shares (31.9% of outstanding) and agrees to tender them into the $1.31/share tender offer.
Nasdaq warns DHC of non-compliance with $1.00 minimum bid price; 180-day cure period
Received Nasdaq notice on Jan 19, 2023: common shares bid price below $1.00 for 30+ consecutive business days.
On March 20, 2025, pursuant to the recommendation of the Nominating and Governance Committee, our Board of Trustees, or the Board, elected Alan L. Felder as an Independent Trustee with a term to expire at our 2025 annual meeting of shareholders.
Jennifer F. Francis, who is retiring from RMR on June 30, 2024, and therefore has resigned as our President and Chief Executive Officer, effective December 31, 2023.
On November 17, 2023, our Board of Trustees, or the Board, appointed Christopher J. Bilotto as our President and Chief Executive Officer, effective January 1, 2024.
On September 25, 2023, Daniel F. LePage and David A. Pierce each resigned as an Independent Trustee of our Board of Trustees, or the Board, effective that day.
On September 25, 2023, Daniel F. LePage and David A. Pierce each resigned as an Independent Trustee of our Board of Trustees, or the Board, effective that day.
Mr. Brown will replace Richard W. Siedel, Jr., who has resigned as our Chief Financial Officer and Treasurer, effective September 30, 2023.
On September 26, 2023, pursuant to the recommendation of the Nominating and Governance Committee of the Board, the Board elected Phyllis M. Hollis as an Independent Trustee to fill one of the vacancies created by Messrs. LePage’s and Pierce’s resignations, and also decreased the size of the Board from seven to six Trustees.
Also on September 26, 2023, the Board appointed Matthew C. Brown as our Chief Financial Officer and Treasurer, effective October 1, 2023.
our Board elected David A. Pierce as an Independent Trustee of our Board with a term to expire at the Company’s 2023 annual meeting to fill the vacancy created by the increase in size of our Board to seven Trustees.
Max materiality 1.00 · Median 0.40 · Most common event other_material